2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $126.39 million. The enterprise value is $181.44 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, before market open.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 51.59 million shares outstanding. The number of shares has increased by 12.76% in one year.
| Current Share Class | 51.59M |
| Shares Outstanding | 51.59M |
| Shares Change (YoY) | +12.76% |
| Shares Change (QoQ) | -5.00% |
| Owned by Insiders (%) | 4.21% |
| Owned by Institutions (%) | 76.63% |
| Float | 43.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.79 |
| Forward PS | 1.96 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.98 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.95, with a Debt / Equity ratio of 1.08.
| Current Ratio | 4.95 |
| Quick Ratio | 4.87 |
| Debt / Equity | 1.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.38% and return on invested capital (ROIC) is -17.07%.
| Return on Equity (ROE) | -35.38% |
| Return on Assets (ROA) | -15.54% |
| Return on Capital (ROIC) | -17.07% |
| Revenue Per Employee | $166,496 |
| Profits Per Employee | -$345,069 |
| Employee Count | 274 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.71% in the last 52 weeks. The beta is 1.77, so 2seventy bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | -20.71% |
| 50-Day Moving Average | 3.37 |
| 200-Day Moving Average | 4.25 |
| Relative Strength Index (RSI) | 35.00 |
| Average Volume (20 Days) | 438,317 |
Short Selling Information
The latest short interest is 4.86 million, so 9.43% of the outstanding shares have been sold short.
| Short Interest | 4.86M |
| Short Previous Month | 4.68M |
| Short % of Shares Out | 9.43% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 12.99 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $45.62 million and -$94.55 million in losses. Loss per share was -$1.82.
| Revenue | 45.62M |
| Gross Profit | -90.73M |
| Operating Income | -142.33M |
| Pretax Income | -156.25M |
| Net Income | -94.55M |
| EBITDA | -133.86M |
| EBIT | -142.33M |
| Loss Per Share | -$1.82 |
Full Income StatementBalance Sheet
The company has $192.40 million in cash and $247.45 million in debt, giving a net cash position of -$55.05 million or -$1.07 per share.
| Cash & Cash Equivalents | 192.40M |
| Total Debt | 247.45M |
| Net Cash | -55.05M |
| Net Cash Per Share | -$1.07 |
| Equity (Book Value) | 228.10M |
| Book Value Per Share | 4.43 |
| Working Capital | 174.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$139.12 million and capital expenditures -$1.78 million, giving a free cash flow of -$140.90 million.
| Operating Cash Flow | -139.12M |
| Capital Expenditures | -1.78M |
| Free Cash Flow | -140.90M |
| FCF Per Share | -$2.73 |
Full Cash Flow StatementMargins
Gross margin is -198.88%, with operating and profit margins of -311.99% and -207.25%.
| Gross Margin | -198.88% |
| Operating Margin | -311.99% |
| Pretax Margin | -207.25% |
| Profit Margin | -207.25% |
| EBITDA Margin | -293.42% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.76% |
| Shareholder Yield | -12.76% |
| Earnings Yield | -74.81% |
| FCF Yield | -111.48% |
Analyst Forecast
The average price target for 2seventy bio is $10.40, which is 324.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.40 |
| Price Target Difference | 324.49% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -2.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -1.49 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.49 |
| Piotroski F-Score | 1 |